Gabapentin Patent Expiration
Gabapentin was first introduced by Viatris Specialty Llc
Gabapentin Patents
Given below is the list of patents protecting Gabapentin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gralise | US7438927 | Methods of treatment using a gastric retained gabapentin dosage |
Feb 26, 2024
(Expired) | Almatica |
| Neurontin |
US7256216 (Pediatric) | Liquid pharmaceutical compositions |
Nov 28, 2022
(Expired) | Viatris |
| Gralise | US7731989 | Gastric retained gabapentin dosage form |
Oct 25, 2022
(Expired) | Almatica |
| Gralise | US8192756 | Gastric retained gabapentin dosage form |
Oct 25, 2022
(Expired) | Almatica |
| Gralise | US8252332 | Gastric retained gabapentin dosage form |
Oct 25, 2022
(Expired) | Almatica |
| Gralise | US8333992 | Gastric retained gabapentin dosage form |
Oct 25, 2022
(Expired) | Almatica |
| Neurontin | US7256216 | Liquid pharmaceutical compositions |
May 28, 2022
(Expired) | Viatris |
| Gralise | US6723340 | Optimal polymer mixtures for gastric retentive tablets |
Oct 25, 2021
(Expired) | Almatica |
| Gralise | US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun 20, 2020
(Expired) | Almatica |
| Neurontin |
US6054482 (Pediatric) | Lactam-free amino acids |
Oct 25, 2017
(Expired) | Viatris |
| Neurontin | US6054482 | Lactam-free amino acids |
Apr 25, 2017
(Expired) | Viatris |
| Gralise | US6340475 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Almatica |
| Gralise | US6635280 | Extending the duration of drug release within the stomach during the fed mode |
Sep 19, 2016
(Expired) | Almatica |
Gabapentin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gabapentin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
